INTEGRATE is an international, multidisciplinary Marie Sklodowska-Curie Doctoral Network funded by the European Commission under Horizon Europe (Grant agreement ID: 101226862), coordinated by the University Center for Psychiatry (UCP) at the University Medical Center Groningen (UMCG). The network aims to train a new generation of interdisciplinary experts to implement psychedelic therapy (PT) in healthcare, addressing challenges such as mechanisms of action, clinical standards, regulatory obstacles, and ethical considerations. The consortium includes 11 academic beneficiaries and 23 associated partners across Europe and worldwide, offering cutting edge research, training schools, and secondments in industry, civil society organizations, regulatory agencies, and more.
The network will provide scientific and translational skills training to 16 Doctoral Candidates (DCs) with three-year fixed-term positions, divided over the 11 beneficiaries in 9 countries in Europe. Each DC will work on an individual PhD project, combining cutting-edge science with training in personal development, ethics, regulation, and societal impact. The program offers excellent supervision, interdisciplinary collaboration, and secondments across academic, clinical, and industry partners to prepare DCs as future leaders in this emerging field.
More information about the network can be found on the consortium website:
www.integrate-dn.eu.
Available DC positions
WP2: Foundational Research – Mechanisms of Action & Understanding Psychedelic Experiences
DC1: The antidepressant efficacy of psilocybin from a pathophysiological perspective (University Medical Center Groningen (UMCG), The Netherlands)
DC2: Understanding the neurobiology of psychedelic therapy from synapse to behavior (Uppsala University (UU), Sweden)
DC3: Identification of EEG and fMRI biomarkers with potential predictive value for psychedelics’ antidepressant effects (National Institute of Mental Health (NIMH), Czechia)
DC4: Mapping the subjective phenomenology of therapeutic and challenging experiences in psychedelic therapy (University Medical Center Groningen (UMCG), The Netherlands, The Netherlands)
DC5: Psychedelics, attachment-related changes, and mental health outcomes (Stockholm University (SU), Sweden)
DC6: Sex/gender differences in psychedelic psychopharmacology (National and Kapodistrian University of Athens (NKUA), Greece)
WP3: Clinical Research – Optimizing Safety and Efficacy
DC7: The role of music and psychotherapeutic support in psychedelic therapy (UCPH), Denmark)
DC8: Set and setting in clinical psychedelic research (Institut national de la santé et de la recherche médicale (INSERM), France)
DC9: Psychotherapy process and psychological intervention techniques in psychedelic therapy: safety and efficacy (Champalimaud Foundation (CF), Portugal)
DC10: Methodological challenges in clinical psychedelic research (Leiden University (LEI), The Netherlands)
DC11: Health economics of psychedelic therapy (Uppsala University (UU), Sweden)
DC12: Analyzing the obstacles and opportunities of different regulatory pathways to patient access for psychedelic therapies (University of Copenhagen (UCPH), Denmark)
DC15*: Evaluating the impact of controlled self-experience with psychedelics in therapist training. A clinical trial (University of Basel (UB), Switzerland)
DC16*: Clinical development of psychedelic-assisted therapy: transdiagnostic mechanisms and contextual factors (University of Zurich (UZH), Switzerland)
WP4: Ethical, Legal, Societal Implications
DC13: Identifying ethical, legal and societal challenges and opportunities for applying psychedelic therapy (University of Groningen (UG), NL)
DC14: Harmonizing Ethical Regulation of Psychedelic Therapy with Broader Medical Practices (Charité Universitätsmedizin Berlin (Charité), DE)
*Swiss-funded positions
Detailed information on the individual DC projects can be found on the consortium website:
www.integrate-dn.eu.